AZ is moving quick to advance R788, licensed from Rigel, into phase III trials for the treatment of rheumatoid arthritis via oral administration. Rigel, for its part, earns a $25 M milestone payment for the effort.
AZ is racing to get R788 (fostamatanib) to the finish line before Pfizer's new drugs hit the scene. Rigel says fostamatinib now will be the focus of one of the largest phase III studies in RA patients to date. Rigel can earn up to $1.24 B with the drug in milestones and royalties. See Fierce Biotech.
Posted by Bruce Lehr September 29th 2010.